Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Inmune Bio r&d expenses
Research and development expenses are spending on new products and technology.
Inmune Bio's R&D Expenses for the twelve months ending Mar 31, 2026 was $16.66M, down 48.1% year over year. For fiscal 2025 it was $20.66M, down 37.7% from the year before. The highest annual figure on record is $33.17M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.66M | -37.7% |
| FY2024 | Dec 31, 2024 | $33.17M | +63.6% |
| FY2023 | Dec 31, 2023 | $20.27M | +18.8% |
| FY2022 | Dec 31, 2022 | $17.07M | -16.9% |
| FY2021 | Dec 31, 2021 | $20.54M | +247.1% |
| FY2020 | Dec 31, 2020 | $5.92M | +80.3% |
| FY2019 | Dec 31, 2019 | $3.28M | -2.2% |
| FY2018 | Dec 31, 2018 | $3.35M | +670.6% |
| FY2017 | Dec 31, 2017 | $435.36K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $3.64M | -52.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.33M | -68.3% |
| Q3 FY2025 | Sep 30, 2025 | $4.89M | -51.5% |
| Q2 FY2025 | Jun 30, 2025 | $5.80M | -17.7% |
| Q1 FY2025 | Mar 31, 2025 | $7.64M | -12.1% |
| Q4 FY2024 | Dec 31, 2024 | $7.35M | +22.4% |
| Q3 FY2024 | Sep 30, 2024 | $10.07M | +68.2% |
| Q2 FY2024 | Jun 30, 2024 | $7.05M | +70.0% |
| Q1 FY2024 | Mar 31, 2024 | $8.69M | +110.3% |
| Q4 FY2023 | Dec 31, 2023 | $6.01M | +76.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.99M | +16.0% |
| Q2 FY2023 | Jun 30, 2023 | $4.15M | -1.0% |
| Q1 FY2023 | Mar 31, 2023 | $4.13M | -4.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.41M | -51.8% |
| Q3 FY2022 | Sep 30, 2022 | $5.16M | -20.9% |
| Q2 FY2022 | Jun 30, 2022 | $4.19M | -6.2% |
| Q1 FY2022 | Mar 31, 2022 | $4.31M | +73.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.07M | +280.2% |
| Q3 FY2021 | Sep 30, 2021 | $6.52M | +175.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.46M | +394.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.49M | +214.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.86M | +114.5% |
| Q3 FY2020 | Sep 30, 2020 | $2.36M | +102.3% |
| Q2 FY2020 | Jun 30, 2020 | $903.00K | +42.3% |
| Q1 FY2020 | Mar 31, 2020 | $793.00K | +29.4% |
| Q4 FY2019 | Dec 31, 2019 | $866.56K | -12.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.17M | +78.4% |
| Q2 FY2019 | Jun 30, 2019 | $634.70K | +120.9% |
| Q1 FY2019 | Mar 31, 2019 | $612.71K | +489.1% |
| Q4 FY2018 | Dec 31, 2018 | $992.20K | – |
| Q3 FY2018 | Sep 30, 2018 | $654.69K | – |
| Q2 FY2018 | Jun 30, 2018 | $287.32K | – |
| Q1 FY2018 | Mar 31, 2018 | $104.01K | – |
See a number that looks wrong?